In this study, we analyzed a thiotepa-based conditioning regimen for allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia, using the EBMT database. A total of 323 patients were identified. The median age was 43 years. Disease status at transplant was first complete remission (CR1) in 48.9%, CR2 in 21.7%, CR3 in 6.2%, while 23.2% of the patients had an active disease at the time of transplant. This was performed from a HLA-matched sibling (49.8%) or a matched-unrelated donor (51.2%). The incidence of acute graft-vs.-host disease (GvHD) (grade > II) was 26.6%, while chronic GvHD occurred in 35.9% of the patients at 1 year (24.6% with extensive disease). With a median follow-up of 16.8 months, the nonrelapse mortality was 12.4 and 25.3% at 100 days and 1 year, respectively. The relapse incidence at 1 year was 33.3% with no difference for patients in CR1 (27%). The one-year leukemia-free survival (LFS) and overall survival (OS) were 57 and 66%, respectively for the entire cohort and 50 and 66%, respectively in patients in CR1. Thiotepa/busulfan 6 melphalan (n 5 213) in comparison to thiotepa/other (n 5 110) conditioning regimen resulted in higher relapse incidence at 1 year (34.9 vs. 30.3%, P 5 0.016) and lower LFS (38.8 vs. 45.9%, P 5 0.0203), while nonrelapse mortality (23.8 vs. 26.3%, n.s.) and OS (59.6 vs. 51.1%, P 5 0.109) did not differ. This large study suggests that a thiotepa-based conditioning for allogeneic transplantation in acute lymphoblastic leukemia is feasible and effective, with the main outcomes being comparable to those achieved with other regimens.
Introduction
Prospective studies focusing on adult patients with acute lymphoblastic leukemia (ALL) treated with intensive chemotherapy report a 2-year overall survival (OS) from 20 to 38% and leukemia-free survival (LFS) ranging from 9 to 21% [1] [2] [3] . Therefore, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an attractive treatment option for improving the outcome of those patients. Allo-HSCT after conventional myeloablative conditioning regimen (MAC) was shown in prospective studies to have a significant effect on the treatment of ALL [4, 5] . In standard risk Philadelphia chromosome (Ph)-negative ALL, the MRC UKALLXII/ECOG 2993 prospective study [4] reported an OS of 53% at 5 years for patients with a sibling donor vs. 45% in the no-donor group (P 5 0.01). Similarly, Cornelissen et al. showed an LFS of 60% at 5 years in the donor group vs. 42% in the no-donor group (P 5 0.01) [5] . In addition, no differences were reported according to the type of donor (OS at 5 years 65% vs. 62% for sibling and unrelated donors, respectively) [6] . In recent years, reduced intensity conditioning (RIC) protocols including fludarabine/busulfan have been used successfully as pretransplantation regimens in patients with high comorbidities scores. Mohty et al reported the outcome of 97 adult ALL patients who received a RIC allo-HSCT with 2-year OS, LFS, and nonrelapse mortality (NRM) of 52 6 9%, 42 6 10% and 18 6 7%, respectively in patients transplanted in CR1 [7] . The same group subsequently compared RIC to MAC pre allo-HSCT in 576 adult ALL patients transplanted from sibling donors in first complete remission (CR1). In multivariate analysis, the type of conditioning regimen was not significantly associated with LFS, while NRM was decreased and relapse rate was increased in RIC recipients [8] .
Thiotepa is an alkylating compound with antineoplastic activity [9, 10] , which has been used in oncology (e.g., breast-, ovarian-, and bladder cancer) for many years [11, 12] . Recently, thiotepa has been used in hematology and, moreover, in HSCT with increasing frequency. Besides its antimalignant stem cell and myelosuppressive activities [13, 14] , which can mimic those of radiation, thiotepa has immunosuppressive properties [15] , making it an attractive agent to be used in the conditioning pretransplantation.
There are several studies reporting the use of thiotepa in allo-HSCT: in the 1990s, Bacigalupo et al. and Rosales et al. published the use of thiotepa in patients with acute leukemia (AML) using MAC [16, 17] . In the first report, thiotepa was administered at a dose of 15 mg/kg in combination with cyclophosphamide. The transplantrelated mortality (TRM) was 29% and the 2-year OS was 57% in these 31 patients with advanced leukemia. Rosales and colleagues investigated in 30 patients the role of thiotepa (2 3 5 mg/kg) in addition to the standard busulfan/cyclophosphamide regimen with comparable results and moderate toxicity rates.
Subsequently, thiotepa was used in RIC regimens [13, 18, 19] . Bacigalupo et al. published in 2007 a 10-year follow-up of thiotepa-based RIC regimen with an impressive outcome [20] . Eighteen of 33 patients survived, the TRM was 18% and the cumulative incidence of relapse-related deaths was 27%. Moreover, several studies could show the feasibility of thiotepa in alternative donor transplants [21] and in cord-blood transplantation [22, 23] . Recently, an EBMT/Eurocord study, comparing single-/double cord-blood transplantations and different conditioning regimens, showed that, at least in the single umbilical cord-blood setting, a conditioning consisting of thiotepa/ busulfan/fludarabine may replace the classical MAC regimens for units with adequate cell dose (>2.5 3 10 7 /kg) [24] .
We recently performed a registry study in which we compared thiotepa-based conditioning regiments to cyclophosphamide/total body irradiation (Cy/TBI) for HSCT in patients with (AML) in CR. A total of 479 patients participated in the study; 121 received thiotepa-based regimens and 358 patients Cy/TBI as part of their pretransplantation conditioning. We showed that transplantation following thiotepa-based conditioning results in a comparable outcome to transplantation with the historical Cy/TBI in AML patients in CR1. Engraftment occurred in 97% in the thiotepa-group vs. 98% in the Cy/TBI group.
Acute graft-vs.-host disease (GvHD) grades II-IV was observed in 25% after thiotepa-containing regimen vs. 35% after TBI. The 2-year cumulative incidence (CI) of chronic GvHD was 40.5% for thiotepa and 41% for Cy/TBI. Those of NRM and relapse were 23.9% (thiotepa) vs. 22.4% (Cy/TBI) and 17.2% (thiotepa) vs. 23.3% (Cy/TBI), respectively. The probabilities of LFS and OS at 2 years were 58.9% (thiotepa) vs. 54.2% (Cy/TBI), and 61.4% (thiotepa) vs. 58% (Cy/TBI), respectively [25] .
In the current study, we analyzed the use of thiotepa in the conditioning regimen for ALL in a retrospective registry study, based on the ALWP of the EBMT database.
Patients and Methods
Study design and data collection. This was a retrospective multicenter analysis. Data were provided and approved for this study by the ALWP of the EBMT registry. The latter is a voluntary working group of more than 600 transplant centers that are required to report all consecutive HSCT procedures and their follow-up once a year. Audits are routinely performed to determine the accuracy of the data. Since 1990, patients provide informed consent authorizing the use of their personal information for research purposes.
Eligible patients for this analysis were adults (age >18 years) with de novo or secondary ALL who underwent a first allogeneic HSCT with a thiotepa-based regimen between 2000 and July 2014. Donors were either HLA-matched siblings or matched-unrelated donors. Haploidentical donors and cord blood transplantations were excluded.
Variables collected included recipient and donor characteristics, disease status at transplant, transplant-related factors including conditioning regimen, immunosuppression, stem cell source, prophylaxis of GvHD and outcome variables (acute and chronic GvHD, relapse, NRM, relapse, LFS and OS). Remission of the leukemia was defined as <5% blasts in the bone marrow (BM) and <1% blast in the peripheral blood, while relapse was defined as disease recurrence with >5% blasts in the BM [26] .
Statistical analysis. The primary end points of the study were OS and LFS. Secondary endpoints included: disease relapse incidence (RI), NRM, engraftment, incidence and severity of acute and chronic GvHD. The starting point for time-toevent analysis was "date of transplantation". OS was defined as the time to death from any cause. Surviving patients were censored at the time of last follow-up. LFS was defined as survival without relapse or progression. RI was defined as time to onset of leukemia recurrence. NRM was defined as death without relapse/progression. Conditioning intensity, engraftment and GvHD were defined and classified as previously described. The probabilities for OS and LFS were estimated from the time of HSCT using the Kaplan-Meier product-limit estimate and were compared by the log-rank test in univariate analysis. Estimates of engraftment, acute and chronic GvHD, NRM and RI were calculated using cumulative incidence rates to accommodate competing risks, and were compared by Gray's test. Death was the competing event for engraftment, GvHD and relapse. Relapse was the competing event for NRM.
Univariate comparisons were done using the log-rank test for OS, LFS, and the Gray's test for RI, NRM and GvHD cumulative incidences. The type I error rate was fixed at 0.05 for determination of factors associated with time to event outcomes. Statistical analyses were performed with SPSS 22.0 (IBM Corp., Armonk, NY, USA) and R 3.1.1 software packages (R Development Core Team, Vienna, Austria).
Results

Patients and disease characteristics
The median age of the 323 ALL patients was 43 (range 18-76) years; 59% were males and 41% females. Disease status at allo-HSCT was CR1 in 48.9%, CR2 in 21.7%, CR3 in 6.2%, while 23.2% of the patients had an active disease at the time of transplant. Transplantation was performed from a HLA-matched sibling (49.8%) or a matchedunrelated donor (50.2%). Sixty-five percent of patients received a MAC and 35% a RIC regimen. Antithymocyte globuline was administered as part of the pretransplant conditioning to 45.1% of the matchedunrelated donor transplants and to 9.9% of the sibling transplants, respectively. The stem cell source was peripheral blood stem cells in 84% of the transplants, while 16% received bone marrow grafts. Table I shows the patients' characteristics. The median follow-up was 16.8 months.
Transplantation outcome
Engraftment. Neutrophil engraftment (defined as >0.5 3 10 9 /L) was 98% within a median day of 15 (range 2-41). Platelet engraftment (defined as >20 3 10 9 /L) was 92% within a median day of 14 (range 7-98). GvHD. The incidence of acute GvHD grade > II was 26.6%. This is comparable with the rate of acute GvHD we observed in thiotepa prior to allo-HSCT in AML [25] . Chronic GvHD occurred in 35.9% at 1 year (24.6% with extensive disease).
Nrm. The NRM was 12.4, 25.3, and 28% at 100 days, 1 and 2 years, respectively. It was significantly higher in patients with an unrelated donor than in those who had a sibling donor (32.1 vs. 18.3%, P 5 0.0042) (Table II; Fig. 1 ). Causes of death, including relapse of original disease, infections and GvHD, were higher for matched-unrelated transplants (44.8, 27.1, and 17.7%) in comparison to sibling transplants (50.7, 23.9, and 12.7%, respectively) (P 5 0.61).
Relapse. The RI at 1 and 2 years was 33.3 and 41%, respectively. No difference was seen in terms of donor-type: 31.9% in sibling donor transplantation and 34.7% in unrelated donor transplantation, respectively (P 5 0.4641) (Table II; Fig. 1 ).
The relapse rate was higher in the thiotepa/busulfan 6 melphalan group than in the thiotepa/other group, namely 34.9 vs. 30.3% (P 5 0.016).
Leukemia-free and overall survival. The 1-year LFS and OS incidences were 57 and 66%, respectively. Those at 2 years were 31 and 43%. Significantly better OS was seen for patients receiving grafts from a sibling donor in comparison to patients transplanted from an unrelated donor (62 vs. 46%, P 5 0.0133) (Table II; Fig. 1) .
A lower LFS was seen for the thiotepa/busulfan 6 melphalan group (38.8%) in comparison to the thiotepa/other group (45.9%, P 5 0.0203).
Results for patients in CR2 were quite encouraging: the 2-year LFS and OS incidences were 34 and 49%. Table II shows the outcome according to donor (Fig. 1 ) and disease status (Fig. 2) at time of allo-HSCT.
Discussion
This large registry survey, conducted by the ALWP of the EBMT, suggests that thiotepa-based conditioning therapy prior to allo-HSCT for adults with ALL is feasible and effective, with the main outcomes being comparable to those achieved with other regimens [27] .
Recently, a German study reported the use of thiotepa in combination with carmustine and fludarabine in patients with ALL undergoing allogeneic HSCT. Their experience indicated the feasibility of this regimen as an alternative to radiotherapy [28] . They could observe a twoyear outcome with comparable results to our study. In our study, most patients received a combination therapy with thiotepa/busulfan 6 melphalan. Those patients had a higher RI and a lower LFS. We observed a higher NRM rate at 1 year for patients transplanted from matched-unrelated donors in comparison to those transplanted from HLA-matched siblings (32.1 vs. 18.3%, P 5 0.0042). This finding was reflected in worse OS for patients transplanted from matched-unrelated donors (46%) in comparison to those transplanted from sibling donors (62%, P 5 0.0133). Antithymocyte globuline was administered as part of the pretransplant conditioning to 45.1% of the matched-unrelated donor transplants and to 9.9% of the sibling transplants, respectively. Incidence of acute GvHD grades II-IV was not significantly different between the two groups (14% for siblings and 15% for matchedunrelated transplants, respectively). We were then looking on causes of death in the two groups, including relapse of original disease, infections and GvHD, that were all higher for matched-unrelated transplants (44.8, 27.1, and 17.7%) in comparison to sibling transplants (50.7, 23.9, and 12.7%, respectively) (P 5 0.61).
Previous publications indicated that ALL patients in CR2 who underwent transplantation with TBI-based conditioning achieved a 2-year LFS and OS of 18-20% and 24-33%, respectively [8] . Our current results with thiotepa-based conditioning for patients with ALL in CR2 is thus quite encouraging, as we observed 2-year LFS and OS incidences of 34 and 49%, respectively. One possible explanation is the lower toxicity in our cohort; the NRM at 2 years was 33%, whereas it is reported to be 28-38% after transplantation with a TBI-based conditioning [8] . We showed an incidence of acute and chronic GvHD comparable to other published regimens, and these results were similar to those from our previous study using thiotepa as a conditioning regimen for allo-HSCT in patients with AML [25] . Another study, using thiotepa in combination with clofarabine and melphalan for a second allo-HSCT in acute leukemia (12 of the 18 reported patients where with ALL), could show an acceptable toxicity, even for a second transplantation. The most common adverse reaction was a reversible elevation of transaminases, associated with clofarabine. Two patients died of TRM and seven relapsed. The 3-year probability of OS was 49% [29] . The ALWP of the EBMT conducted a study [30] , investigating the safety and toxicity of thiotepa in patients undergoing allo-HSCT with AML. Mucositis occurred in 46.8% and the incidence of sinusoidal obstruction syndrome was 4%.
In conclusion, in this registry-based study of ALL patients who received thiotepa prior to allogeneic HSCT, with more that 50% of patients transplanted in CR21, we demonstrated that thiotepa is feasible and safe, with good transplantation outcome. These data should be confirmed in a well-designed multicenter prospective study. 
